Connect with us

Headlines

100-Year-Old Optometrist Has No Plans to Retire

‘I don’t think it’s unusual,’ he says of his long career. ‘But everyone else does.’

mm

Published

on

Dr. Daniel Nast has been in the optometry business for a long time — a really long time.

Nast recently turned 100, the Chicago Tribune reports.


He sees patients at the Mind-Eye Institute in Northbrook a couple of times a week. He also works at another practice on Saturdays.

“I don’t think it’s unusual. But everyone else does,” he said of his long career. He began practicing optometry 75 years ago.

“Being 100 years old, I think that’s what’s keeping him going, is working,” said Nast’s son, Richard Nast, who is an optician.

Advertisement

The elder Nast said he plans to work as long as he’s able because he enjoys helping people.

Read more at the Chicago Tribune

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at [email protected].

Advertisement

SPONSORED VIDEO

SPONSORED BY KENMARK

Jump In — the Water’s Fine!

With a salute to summer’s shimmery, mermaid colors and warm weather-loving shades, Kenmark Eyewear celebrates this summer’s Aloha spirit with eyewear from Vera Wang, Kensie, Zac Posen and the Original Penguin Collection!

Promoted Headlines

Headlines

VSP Expands Member Access to Eyecare During COVID-19 Pandemic

The expansion lasts through April 30.

mm

Published

on

RANCHO CORDOVA, CA – VSP Global has expanded access to essential medical eye care services for most VSP Vision Care insured members and their covered dependents in response to the COVID-19 pandemic. The police went into effect April 1 and runs through April 30 for most VSP members who did not already have this benefit.

These members now have access to supplemental medical eyecare for the detection, treatment and management of ocular and visual conditions, and can see their VSP network doctor in-person or remotely to get treatment for a variety of conditions including conjunctivitis, eye trauma and sudden changes to vision, the company said in a press release. Eligible members can also use their routine VSP coverage for lost or broken glasses or replacement contact lenses to meet immediate eyewear needs by contacting their VSP network doctor.

See Our Full Schedule of COVID-19 Webinars
Webinars

See Our Full Schedule of COVID-19 Webinars

Managing Through COVID-19: How Opticians and Independent Eyewear Retailers are Faring [Webinar Replay]
Webinars

Managing Through COVID-19: How Opticians and Independent Eyewear Retailers are Faring [Webinar Replay]

Managing Through COVID-19: Corona Town Hall [Webinar Replay]
Webinars

Managing Through COVID-19: Corona Town Hall [Webinar Replay]

“Expanding essential medical eye care services for VSP members is critical to ensure they can access the care they need in this COVID-19 environment,” said Michael Guyette, president and CEO of VSP Global. “In doing so, we can help keep VSP members and their VSP network doctors connected, lowering the likelihood of our members visiting primary care physicians or emergency rooms and reducing demand on our strained healthcare system during this unprecedented time.”

Recently, optometrists were included as essential critical infrastructure workers as part of guidance from the U.S. Cybersecurity and Infrastructure Security Agency. Additionally, as new legislation allows optometric physicians the flexibility and recognition to treat patients remotely, a webinar resource for VSP network doctors, “Optometry & Telemedicine During COVID-19,” is now available from Premier Academy360. During the COVID-19 pandemic, telemedicine can make it safer for doctors and patients by allowing doctors to communicate, evaluate and manage certain eye health needs, the release explains. The webinar explores guidelines and how a practice can implement telemedicine, as well as information about telemedicine coverage through VSP plans. It is available here.

Additionally, Eyefinity is providing telemedicine functionality to all Eyefinity EHR users to enable efficient documentation and coding of remote patient consultations. This supports VSP network doctors’ ability to ramp up telemedicine capabilities for patients with essential eye care needs. In the coming weeks, Eyefinity is also slated to make available patient video chat technology for Eyefinity EHR users.

Continue Reading

Headlines

EyePoint Cuts Jobs Due to COVID-19 Crisis

The company makes Dexycu and Yutiq.

mm

Published

on

WATERTOWN, MA — EyePoint Pharmaceuticals Inc. is planning workforce reductions in response to the coronavirus pandemic.

The company (NASDAQ: EYPT) said it expects $7 million in annual savings from the reductions and $10 million in one-time savings from other planned expenditure cancellations and deferrals. It did not say how many employees would lose their jobs.

See Our Full Schedule of COVID-19 Webinars
Webinars

See Our Full Schedule of COVID-19 Webinars

Managing Through COVID-19: How Opticians and Independent Eyewear Retailers are Faring [Webinar Replay]
Webinars

Managing Through COVID-19: How Opticians and Independent Eyewear Retailers are Faring [Webinar Replay]

Managing Through COVID-19: Corona Town Hall [Webinar Replay]
Webinars

Managing Through COVID-19: Corona Town Hall [Webinar Replay]

EyePoint has two commercial products: Dexycu, the first approved intraocular product for the treatment of postoperative inflammation, and Yutiq, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

The company said in a press release that it’s experienced “a significant decline in product demand associated with shut-downs of customer facilities and postponements of elective surgical procedures in response to COVID-19.”

“COVID-19 driven closures have significantly impacted our customer base and this commercial reorganization is necessary to focus the Company’s resources on continuing to serve patients who are still being treated with YUTIQ and DEXYCU,” said Nancy Lurker, president and CEO of the firm. “We have prioritized our overall spending to focus on a more targeted commercial footprint, conserve cash and to continue advancing EYP-1901, a six-month potential treatment for wet age-related macular degeneration, toward clinical development.

“Our patients, employees, shareholders and the ocular disease community remain our top priorities as we navigate through the COVID-19 pandemic. We want to recognize and thank those affected by this reorganization for their dedication to EyePoint and our patients, and we will work to make their transitions to other opportunities as smooth as possible.”

Advertisement

Other details from the release:

Dedicated to Delivering Our Innovative Ocular Disease Treatments to Patients

EyePoint is committed to providing uninterrupted access to our products during the COVID-19 pandemic for those patients who are in essential need of treatment. Our supply chains for YUTIQ and DEXYCU are robust and have not been interrupted during the pandemic. The Company has ample supply of API and other raw materials for YUTIQ and DEXYCU, and EyePoint continues to produce finished product for commercial sale. Our commercial team is providing ongoing support services for patients and physician offices on an as-needed basis, while respecting the need to maintain social distancing.

Focusing of Commercial Operations in Response to COVID-19 Impact on Commercial Markets

The Company will downsize its current workforce, with reductions coming primarily from the external DEXYCU sales force and supporting commercial operations as cataract surgery is considered a non-essential procedure due to the pandemic. The Company plans to allocate its remaining DEXYCU commercial resources to high-volume ambulatory surgery centers (ASCs) in key U.S. regions, subject to the availability of such ASCs to perform elective cataract surgery upon the lifting of restrictions associated with the COVID-19 pandemic. The Company will continue to invest in its YUTIQ commercial operations, as treatments for patients suffering from non-infectious uveitis affecting the posterior segment of the eye continue to be deemed essential during the COVID-19 pandemic, given that irreversible blindness is a potential consequence of delaying treatment.

The reorganization is  Based on these actions, coupled with cash conservation activities, the Company is able to reconfirm its expected cash runway into 2021 under current assumptions for the duration of the COVID-19-related closures across the U.S.

The Company estimates that it will record approximately $0.6 million for severance and other costs related to the workforce reduction in the second quarter of 2020. Further details on the financial implications of the corporate restructuring will be included in the Company’s 10-Q for the first quarter of 2020 and other filings to be made with the Securities and Exchange Commission.

Business Continuity Plan to Protect Employees and Advance Development Pipeline

In early March 2020, the Company mandated a work from home policy for all employees who are not deemed essential to our manufacturing operations and suspended all non-essential travel. The Company has maintained a rotating, limited schedule to ensure continued production of YUTIQ and DEXYCU with heightened safety precautions for our employees.

Research and development initiatives remain on schedule. In March, the Company initiated a good laboratory practice (GLP) toxicology study for EYP-1901, a six-month sustained release anti-VEGF potential treatment for wet age-related macular degeneration. We expect to file an investigational new drug (IND) application for this program in the fourth quarter of 2020 with a Phase 1 clinical trial to commence shortly thereafter.

The Company continues to assess its policies, business continuity plans and employee support needs during the COVID-19 pandemic.

Continue Reading

Headlines

New Mido Dates Announced

The trade show will be held Feb. 6-8, 2021.

mm

Published

on

The 50th edition of the Mido eyewear trade show has been scheduled for Feb. 6-8, 2021.

“The ongoing Covid-19 pandemic in Italy and its swift spread to the rest of the world, along with doubts about when the crisis will normalize globally, have forced us to make the painful, but crucial, decision to safeguard exhibitors and visitors, buyers and stakeholders, staff and everyone involved in the organization, management and operation of the show,” said Mido President Giovanni Vitaloni. “The 50th anniversary edition is being moved to 2021 and we are convinced it will bring a new lease on life to the eyewear industry in Italy and abroad. Our focus, and that of all industry professionals, is to inject new vitality into a healthy economic system that – although slowed by the public health crisis – has never lost its driving force.”

See Our Full Schedule of COVID-19 Webinars
Webinars

See Our Full Schedule of COVID-19 Webinars

Managing Through COVID-19: How Opticians and Independent Eyewear Retailers are Faring [Webinar Replay]
Webinars

Managing Through COVID-19: How Opticians and Independent Eyewear Retailers are Faring [Webinar Replay]

Managing Through COVID-19: Corona Town Hall [Webinar Replay]
Webinars

Managing Through COVID-19: Corona Town Hall [Webinar Replay]

In February, the show’s board of directors announced that it would postpone the 2020 edition until dates, not yet determined at that point, between the end of May and mid June because of the coronavirus outbreak. The show had originally been scheduled for Feb. 29 to March 2, 2020.

The dates for the event in 2021 are about three weeks earlier than the show is normally held each year. It will be held at Fiera Milano Rho.

“A significant change, one we had planned to announce during the 2020 edition,” Vitaloni said. “By
moving the date forward several weeks, we can give an additional boost to the eyewear business globally and in Italy.”

Vitaloni continued: “During these perplexing times, in an ongoing scenario of diminishing revenues and increasing costs, national and international businesses are struggling to strike a balance between the need to keep working and the essential task of ensuring the safety of their employees. This is why we must make certain that, once the pandemic has peaked, businesses know they can count on MIDO to showcase their collections, machinery, ophthalmic innovations, tech inventions and, each in their own field of specialization, get back to doing business. By fostering an alliance between exhibitors and visitors, in a climate of restored confidence, MIDO can play a crucial role in the recovery.”

While awaiting MIDO 2021, the MIDO4U digital platform is a key resource that connects exhibitors with international buyers.

“Of course, the digital platform cannot replace an actual fair, where people can mingle and talk business,” Vitaloni said, “but it is an accessible means of real, albeit virtual, interaction that ensures the industry a viable way to continue to build business relationships.”

 

Continue Reading

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular